I share Senator Murray's concern with regard to the fact that with the FDA, as the agency has grown with large new requirements to publish regulations for food, tobacco, other things, we have seen additional delays in getting guidances and regulations necessary for medical product innovation and the public health finalized and approved.
Roberts expresses concern about FDA delays affecting medical product innovation.
Share
More from Pat Roberts
I strongly agree with USTR's assessment that we have significant problems related to intellectual property and other market access-related issues with China.
Over the past year, President Trump, as we've seen it, has broken promise after promise to our workers and made it easier for corporations to put workers' lives and safety at risk.
These very important missions will be even better served with the necessary key leadership in place.
Other voices in this conversation
